Literature DB >> 24337199

[Early symptoms of dermatomyositis and antisynthetase syndrome].

B Maurer1.   

Abstract

INTRODUCTION: The early diagnosis of rheumatic diseases is becoming increasingly important. This particularly includes inflammatory myopathies which are multisystemic disorders with visceral involvement that are associated with high morbidity and mortality. Early diagnosis before the development of irreversible organ involvement is, therefore, of great importance.
METHODS: This report provides information on early signs and symptoms of dermatomyositis and antisynthetase syndrome. Furthermore, screening methods which allow early diagnosis including involvement of internal organs are discussed. In addition, clinical and serological subtypes and their impact on prognosis are described.

Entities:  

Mesh:

Year:  2013        PMID: 24337199     DOI: 10.1007/s00393-013-1196-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  33 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis.

Authors:  M Fathi; S Barbasso Helmers; I E Lundberg
Journal:  J Intern Med       Date:  2011-10-31       Impact factor: 8.989

3.  Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies.

Authors:  Hajime Yoshifuji; Takao Fujii; Shio Kobayashi; Yoshitaka Imura; Yoshimasa Fujita; Daisuke Kawabata; Takashi Usui; Masao Tanaka; Sonoko Nagai; Hisanori Umehara; Tsuneyo Mimori
Journal:  Autoimmunity       Date:  2006-05       Impact factor: 2.815

4.  Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy.

Authors:  Louise K Mercer; Tonia L Moore; Hector Chinoy; Andrea K Murray; Andy Vail; Robert G Cooper; Ariane L Herrick
Journal:  Rheumatology (Oxford)       Date:  2010-05-18       Impact factor: 7.580

Review 5.  Inclusion body myositis and myopathies.

Authors:  R C Griggs; V Askanas; S DiMauro; A Engel; G Karpati; J R Mendell; L P Rowland
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

Review 6.  Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?

Authors:  Geoffrey R Connors; Lisa Christopher-Stine; Chester V Oddis; Sonye K Danoff
Journal:  Chest       Date:  2010-12       Impact factor: 9.410

Review 7.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 8.  Idiopathic interstitial pneumonias: CT features.

Authors:  David A Lynch; William D Travis; Nestor L Müller; Jeffrey R Galvin; David M Hansell; Philippe A Grenier; Talmadge E King
Journal:  Radiology       Date:  2005-07       Impact factor: 11.105

Review 9.  Pulmonary manifestations of the idiopathic inflammatory myopathies.

Authors:  Meena Kalluri; Chester V Oddis
Journal:  Clin Chest Med       Date:  2010-09       Impact factor: 2.878

10.  Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies.

Authors:  Cecilia Grundtman; Joseph Bruton; Takashi Yamada; Therese Ostberg; David S Pisetsky; Helena Erlandsson Harris; Ulf Andersson; Ingrid E Lundberg; Håkan Westerblad
Journal:  FASEB J       Date:  2009-10-16       Impact factor: 5.191

View more
  2 in total

1.  [Raynaud's phenomenon : Practical management].

Authors:  C Drerup; A Maier; J Ehrchen
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

2.  Characterisation of Disease Patterns of Dermatomyositis with Different Initial Manifestations.

Authors:  Yue Sun; Dai-Feng Li; Yin-Li Zhang; Xu Liang; Tian-Fang Li
Journal:  Int J Gen Med       Date:  2022-08-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.